Medicus Pharma Ltd. has completed enrollment of 90 patients in its Phase 2 clinical study (SKNJCT-003) evaluating the safety and efficacy of the Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of nodular basal cell carcinoma $(BCC)$ of the skin in the United States. The topline results of this trial are expected to be released before the end of the first quarter of 2026, with an End-of-Phase 2 (EOP2) meeting with the FDA planned for the first half of 2026. The study is being conducted at nine clinical sites in the US. Additionally, Medicus Pharma has initiated a separate study (SKNJCT-004) in the United Arab Emirates and has received regulatory and ethical approvals to expand the Phase 2 study to the United Kingdom. No final results have been presented yet; they are expected in the future.